Besides critiquing the Congressional Budget Office for failing to cite and discuss evidence from independent sources that suggest that the net corporate costs of pharmaceutical research and development costs are much lower than industry advocates claim, Light's review showed how these high estimates are constructed realities that one can reconstruct by using different assumptions, data, or calculations and come up with much lower estimates. In their reply here, DiMasi, Hansen, and Grabowski unwittingly reinforce that point.

The text of this article is only available as a PDF.
You do not currently have access to this content.